WP
EDIT icon

Woodline Partners’s Editas Medicine EDIT Stock Holding History

Woodline Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Buy
+3,555,497
New +$10.4M 0.04% 497
2025
Q3 		– Sell
-846,399
Closed -$1.86M – 932
2025
Q2 		$1.86M Buy
+846,399
New +$1.38M 0.01% 731
2025
Q1 		– Sell
-838,419
Closed -$1.06M – 932
2024
Q4 		$1.06M Sell
838,419
-62,002
-7% -$158K 0.01% 748
2024
Q3 		$3.07M Sell
900,421
-70,070
-7% -$305K 0.03% 438
2024
Q2 		$4.53M Buy
970,491
+75,491
+8% +$426K 0.04% 349
2024
Q1 		$6.64M Sell
895,000
-401
-0% -$3.33K 0.06% 333
2023
Q4 		$9.07M Sell
895,401
-2,364,309
-73% -$20.8M 0.1% 241
2023
Q3 		$25.4M Buy
3,259,710
+510,405
+19% +$4.38M 0.3% 99
2023
Q2 		$22.6M Buy
2,749,305
+102,685
+4% +$895K 0.27% 110
2023
Q1 		$19.2M Buy
2,646,620
+567,872
+27% +$5.05M 0.26% 108
2022
Q4 		$18.4M Buy
+2,078,748
New +$22.8M 0.25% 123
2022
Q3 		– Sell
-1,016,891
Closed -$12M – 774
2022
Q2 		$12M Buy
1,016,891
+994,020
+4,346% +$13.3M 0.19% 152
2022
Q1 		$435K Buy
+22,871
New +$425K 0.01% 522

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners's EDIT Position: Q2 2026 in Review

Woodline Partners opened a new position in Editas Medicine (EDIT) in Q2 2026: 3,555,497 shares worth $11.5M. The stake represents 0.04% of the portfolio and ranks #497 among its holdings. This is a return to the name: Woodline Partners previously reported a position in EDIT as recently as Q2 2025.

Woodline Partners first reported a position in EDIT in Q1 2022 and has held it in 13 quarters since. The position peaked at $25.4M in Q3 2023. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Woodline Partners held 3,555,497 shares of Editas Medicine worth $11.5M as of Q2 2026.
  • Editas Medicine was a new Woodline Partners position in Q2 2026.
  • Editas Medicine made up 0.04% of Woodline Partners's portfolio in Q2 2026, its #497 holding.
  • Woodline Partners first reported a position in Editas Medicine in Q1 2022 and has held it in 13 quarters since.
  • Woodline Partners's Editas Medicine position peaked at $25.4M in Q3 2023.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.